Singapore is a Top Index-Ranked Smart City. How are They Collaborating with China to Build Asian Sustainability?

Singapore was the highest index-ranked Smart City in the world in 2021, followed by a tie between Zurich and Oslo, according to Statista. While China did not have any cities listed on the index-ranked list, they are certainly working to build digital and business collaborations with Singapore through their Smart City Initiative, which was launched in 2019.

What are some of the specifics that Singapore and China are working on with this initiative? There are a total of eight agreements and 14 projects between the two. Some of the projects include planning to reduce carbon dioxide emissions and boost how batteries are used for electric vehicles via artificial intelligence.

With varied dynamics between the environments and cultures in Singapore and China, how do their approaches differ when it comes to building Smart Cities? Paul Doherty, CEO of The Digit Group, Inc, provides insight into Smart City marketing and success rates.

Paul’s Thoughts

“So here’s the thing. Singapore and China have done some good work when it comes to these smart city testings and projects, and they’ve been doing this now for about three years. Being a resident and of China and having my core business be registered in Singapore, I have a keen interest in trying to understand what the success rates and what the measures are.

When these announcements are made always keep in mind that Singapore is excellent marketing itself, especially as a smart nation, smart city. We’ve been doing this since 2014 when the Office of Smart Cities was opened up by the Prime Minister. What I find interesting about this particular announcement is there was no mention of the terms test beds or pilots.

These are projects because in the past what happened was when there was a pilot test, let’s say in, the Jerome Lake District, in the western part of Singapore, they would invite the mass media, the CNNs, and the BBCs, and whatnot. They would do a test for a period of time, and then shelve it, for use in future times. The test beds though, are much more significant, right? They’re, the ones that say, all right, we’re gonna put money into this thing.

There’s an IP associated with co-development, right? But then they shift a bit in order to make it work in a place like Shenzhen, which is where this agreement is. Shenzhen is a southern city in China. It’s known as the Silicon Valley of China. It’s where Tencent and Huawei, other large IT-based organizations are.

So it’ll be interesting to see how these 14 different test beds work out both in Singapore and in China, and if they’re actually going to be benchmarking themselves on this, it’s something to take a keen look at and always learn.”

Follow us on social media for the latest updates in B2B!

Image

Latest

ESA
ESA Success Requires Strategy, Infrastructure, and Support Beyond Legislation
April 21, 2025

As education savings accounts (ESAs) gain traction across the United States, the conversation is shifting from policy debates to the complexities of implementation. Fueled by post-pandemic dissatisfaction with traditional school models and a desire for more customizable educational options, ESAs are being adopted in a growing number of states, often under “universal” frameworks. But…

Read More
supply chain data analytics
Supply Chain Data Analytics Fails Without Clean Data, Ventagium Delivers the Fix
April 21, 2025

Supply chain leaders face an overwhelming volume of siloed data across ERPs, TMS platforms, and warehouse systems, yet few know how to align it for smarter decisions. The stakes are rising fast. According to Capgemini’s 2024 report Data: A Powerful Ally in Tackling Scope 3 Emission Reduction Targets, 85% of organizations cite data access…

Read More
cancer immunotherapy
What’s Next in Preclinical Cancer Immunotherapy Research?
April 19, 2025

As the field of cancer immunotherapy rapidly evolves, researchers are turning to next-generation in vitro technologies to replicate the complexities of the tumor microenvironment with unprecedented fidelity. Organoid platforms and ex vivo patient-derived tissue models are transforming how scientists approach preclinical testing, offering deeper mechanistic insights and better predictive power for therapeutic response. With immunotherapies…

Read More
vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More